TuHURA Biosciences ( (HURA) ) just unveiled an update.
On March 18, 2025, TuHURA Biosciences announced its intention to acquire Kineta, Inc., which will enhance its product pipeline with Kineta’s VISTA-101 development program. The merger is expected to bring significant synergies and strengthen TuHURA’s position in the biopharmaceutical sector, although it involves various risks and uncertainties related to regulatory approvals and market conditions.
More about TuHURA Biosciences
TuHURA Biosciences operates in the biopharmaceutical industry, focusing on developing innovative cancer immunotherapies. The company is known for its tumor microenvironment modulators and innate immune agonists, with a strong emphasis on overcoming resistance to cancer immunotherapy.
YTD Price Performance: -41.12%
Average Trading Volume: 207,326
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $96.41M
Learn more about HURA stock on TipRanks’ Stock Analysis page.